World Lung 2020 – amivantamab puts more data behind the hype
But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?
A turn-up for Spectrum’s book
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
The first test of Spectrum’s shift
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
World Lung preview – Astra takes on Roche
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
